0570F37359 | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

0570F37359
Health Canada Patents

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

evonik-m-2025-09-08

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

0570F37359

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 2 KDMF, 1 NDC API, 1 Listed Suppliers

3 API Suppliers
2 KDMF
1 NDC API
1 Listed Suppliers

DEVELOPMENTS

15 Drugs in Development

15 Drugs in Development

INTERMEDIATES

26 Intermediate Suppliers

26 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers, 1 FDA Orange Book, 1 Canada

2 FDF Dossiers
1 FDA Orange Book
1 Canada

DIGITAL CONTENT

4 News #PharmaBuzz

4 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 3 Annual Reports

1 US Medicaid Prescriptions
3 Annual Reports

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

47 US Patents, 4 Health Canada Patents

47 US Patents
4 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4Gilead Sciences Canada Inc.

filter Patent Reset all filters

4 All

01 12682230

02 12794669

03 12815082

04 12877005

filter Product Reset all filters

4 All

01 4SOFOSBUVIR | VELPATASVIR | VOXILAPREVIR

filter Dosage Reset all filters

4 All

01 4TABLET

filter Exp Date Reset all filters

4 All

01 12028-03-26

02 12031-03-31

03 12032-11-16

04 12033-07-02

Product Main Page

01

Gilead Sciences Canada Inc.

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

ESCRS

Not Confirmed

Gilead Sciences Canada Inc.

Country

ESCRS

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-03-26

Date Granted : 2014-04-22

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

Brand Name : VOSEVI

Patent Number : 2682230

Filing Date : 2008-03-26

Strength per Unit : 400 mg / 100 mg / 100 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2028-03-26

Date Granted : 2014-04-22

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Gilead Sciences Canada Inc.

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

ESCRS

Not Confirmed

Gilead Sciences Canada Inc.

Country

ESCRS

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-03-31

Date Granted : 2016-10-11

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

Brand Name : VOSEVI

Patent Number : 2794669

Filing Date : 2011-03-31

Strength per Unit : 400 mg / 100 mg / 100 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2031-03-31

Date Granted : 2016-10-11

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Gilead Sciences Canada Inc.

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

ESCRS

Not Confirmed

Gilead Sciences Canada Inc.

Country

ESCRS

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-11-16

Date Granted : 2015-07-07

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

Brand Name : VOSEVI

Patent Number : 2815082

Filing Date : 2012-11-16

Strength per Unit : 400 mg / 100 mg / 100 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-11-16

Date Granted : 2015-07-07

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Gilead Sciences Canada Inc.

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

ESCRS

Not Confirmed

Gilead Sciences Canada Inc.

Country

ESCRS

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-07-02

Date Granted : 2016-12-13

SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR

Brand Name : VOSEVI

Patent Number : 2877005

Filing Date : 2013-07-02

Strength per Unit : 400 mg / 100 mg / 100 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-07-02

Date Granted : 2016-12-13

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!